AFP - AstraZeneca files US action against generic Crestor drugs
LONDON (AFP) — Anglo-Swedish pharmaceuticals giant AstraZeneca said Wednesday it would sue seven generic drug manufacturers in the United States to defend its patent of cholesterol treatment Crestor.
The world’s top pharmaceuticals companies are facing fierce competition from generic drugs, which are made by other companies once the patent protection expires or are very similar treatments.
“AstraZeneca today announced that it has filed patent infringement actions in United States District Court, District of Delaware, against seven generic drug manufacturers, which have submitted Abbreviated New Drug Applications for CrestorTM,” the company said in a statement.
Related Results
Evening Standard, London, Market Report Column.
US scientist casts doubt on AstraZeneca’s Crestor
AstraZeneca’s Crestor off to strong start in USA; overall performance on track.
AstraZeneca warns of delay to Crestor launch
US scientist casts doubt on AstraZeneca’s Crestor
AstraZeneca recently cited the effect of generic drugs on its earnings when it posted a steep 15-percent drop in third-quarter profits last month. …
Read the full article with a Free Trial at MyWire.
